A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage IIIb or IV Non-Squamous NSCLC

Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Histologically or cytologically confirmed Stage IIIB or Stage IV non-squamous
non-small cell lung cancer (NSCLC)

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- For patients who received prior adjuvant chemotherapy: a treatment-free interval of
at least 12 months since last chemotherapy cycle

- Adequate tissue for central IHC assay of Met receptor, and EGFR testing if EGFR
status is unknown

- Radiographic evidence of disease

Exclusion Criteria:

- Prior systemic treatment for Stage IIIB or IV non-squamous NSCLC

- Evidence of mixed NSCLC with a predominance of the squamous cell type

- Prior exposure to experimental treatment targeting either the HGF or Met pathway

- Patients with tumors confirmed to have EGFR-activating mutations who are suitable for
anti-EGFR therapy (e.g. gefitinib or erlotinib), as determined by the investigator

- Known central nervous system (CNS) disease, other than stable, treated brain
metastases

- History of another malignancy in the previous 3 years, except for history of in situ
cancer or basal or squamous cell skin cancer

- Uncontrolled diabetes

- Pregnant or lactating women

- Impaired bone marrow, liver or renal function (as defined by protocol)

- Significant history of cardiovascular disease

- Positive for HIV infection